A practical reference on PPARδ: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-01-28 and is reviewed periodically as new material appears.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Typical form of reference material |
| Solubility | Low in water; soluble in DMSO | Used to prepare stock solutions |
| Typical storage | -20 °C, desiccated, protected from light | Common laboratory practice |
| Analytical method | LC-MS/MS | Detects parent compound and metabolites |
| Common test matrix | Urine or blood | Used in anti-doping analysis |
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
==== Medal of the Royal Victorian Order (RVM) ==== In Silver John Nelson Hart, Gamekeeper, Sandringham Estate. Keith Hodson, Stud Hand, Royal Studs. Constable Anthony Claud James, Royalty and Diplomatic Protection Department, Metropolitan Police. John Trodden Kerr, Leading Palace Attendant, Windsor Castle. Leading Marine Engineering Mechanic (Mechanical) Andrew Kevin King, HM Yacht Britannia. Richard Clive Lines, Painter, Sandringham Estate. Musician William Huw Morris, HM Yacht Britannia. Sergeant Paul Andrew George Murrell, Norfolk Constabulary. Peter Leonard Riches, Foreman Gardener, Crown Estate, Windsor. Constable Mervyn John Shrubb, Royalty and Diplomatic Protection Department, Metropolitan Police. David Wetherill, Sacristan, St George's Chapel, Windsor Castle. John Herbert Willison, lately of Truefitt & Hill Limited. Acting Petty Officer Marine Engineering Mechanic (Electrical) Barry John Winstone, HM Yacht Britannia.
== In popular culture == Catherine Hernandez's 2017 novel Scarborough centres on the coming of age of three children living in the Galloway Road neighbourhood of Scarborough. Scarborough is a 2021 adaptation of the novel Scarborough. Brother is an adaption of the novel of the same name, also set in the Galloway Road neighbourhood. Morningside is a 2024 film about seven characters who meet at a community centre in Scarborough.
The Lutheran church was the state church of the Kingdom of Hanover, with the King being summus episcopus (Supreme Governor of the Lutheran Church). Regional consistories supervised church and clergy. These were in Aurich, a simultaneously Lutheran and Calvinist consistory dominated by Lutherans (for East Frisia) and the Lutheran consistories in Hanover (for the former Electorate of Brunswick-Lüneburg proper), in Ilfeld (for the County of Hohenstein, a Hanoverian exclave in the Eastern Harz mountains), in Osnabrück (for the former Prince-Bishopric of Osnabrück), in Otterndorf (existed 1535–1885 for the Land of Hadeln) as well as in Stade (existed 1650–1903, until 1885 for the former Bremen-Verden proper without Hadeln, then including the complete Stade region). A general superintendent chaired each consistory. In 1848, the Lutheran parishes were democratised by the introduction of presbyteries (German: Kirchenvorstände, singular Kirchenvorstand; literally: church boards), elected by all major male parishioners and chairing each congregation in co-operation with the pastor, being before the sole chairman. This introduction of presbyteries was somewhat revolutionary in the rather hierarchically structured Lutheran church. In 1864, Carl Lichtenberg, Hanoverian minister of education, cultural and religious affairs (1862–65), persuaded the Ständeversammlung (lit. Estates Assembly, the Hanoverian parliament) to pass a new law as to the constitution of the Lutheran church. The constitution provided a state synod (parishioners' parliament, German: Landessynode).
Sources: en.wikipedia.org
This results in the Fe2+ ion switching to a low-spin configuration, resulting in a 20% decrease in ionic radius so that now it can fit into the porphyrin ring, which becomes planar. Additionally, this hydrogen bonding results in the tilting of the oxygen molecule, resulting in a Fe–O–O bond angle of around 120° that avoids the formation of Fe–O–Fe or Fe–O2–Fe bridges that would lead to electron transfer, the oxidation of Fe2+ to Fe3+, and the destruction of hemoglobin. This results in a movement of all the protein chains that leads to the other subunits of hemoglobin changing shape to a form with larger oxygen affinity. Thus, when deoxyhemoglobin takes up oxygen, its affinity for more oxygen increases, and vice versa. Myoglobin, on the other hand, contains only one heme group and hence this cooperative effect cannot occur. Thus, while hemoglobin is almost saturated with oxygen in the high partial pressures of oxygen found in the lungs, its affinity for oxygen is much lower than that of myoglobin, which oxygenates even at low partial pressures of oxygen found in muscle tissue. As described by the Bohr effect (named after Christian Bohr, the father of Niels Bohr), the oxygen affinity of hemoglobin diminishes in the presence of carbon dioxide.
== Combined endpoint == Some studies will examine the incidence of a combined endpoint, which can merge a variety of outcomes into one group. For example, the heart attack study above may report the incidence of the combined endpoint of chest pain, myocardial infarction, or death. An example of a cancer study powered for a combined endpoint is disease-free survival; trial participants experiencing either death or discovery of any recurrence would constitute the endpoint. Overall Treatment Utility is an example of a multidimensional composite endpoint in cancer clinical trials. Regarding humane endpoints, a combined endpoint may constitute a threshold where there is enough cumulative degree of disease, symptoms, signs or laboratory abnormalities to motivate an intervention.
The 2016 Olympic medals were the largest diameter of any medals presented at the Olympics up to this point. The golds were purer than any presented at all preceding Olympics. The silvers were made from recycling mirrors, solder, and X-ray plates. Just under half of the copper used in the bronze medals was recycled from normal operations at the Brazilian Mint. The reverse of the medals features Nike, the Greek goddess of victory.
Sources: en.wikipedia.org
=== Paroxetine hydrochloride === Paroxetine hydrochloride was developed in the 1970s by scientists at Ferrosan and patented as US4007196A in 1976. Ferrosan licensed this patent to the Beecham Group, which later merged into GSK (GlaxoSmithKline at the time). The paroxetine developed at that time was paroxetine anhydrate, which is a chalky powder that was hygroscopic. This made it difficult to handle. In late 1984, while scaling up the production of paroxetine, a new crystal form (hemihydrate) suddenly appeared at two Beecham sites in the UK within a few weeks of each other. In the presence of water or humidity, mere contact with hemihydrate converts anhydrate into hemihydrate. Alan Curzons, working for GSK, wrote down the "Paroxetine Polymorphism" memorandum on May 29, 1985, a memorandum vital to later litigation. When the patent for paroxetine anhydrate (the "original" polymorph) ran out, other companies wanted to make generic antidepressants using the chemical. The problem was that, by the time other companies began manufacturing, Earth's atmosphere was already seeded with microscopic quantities of paroxetine hemihydrate from GSK's manufacturing plants, which meant that anyone trying to manufacture the original polymorph would find it transformed into the still-patented version, which GSK refused to give manufacturing rights for. Thus, GSK sued the Canadian generic pharmaceutical company Apotex (SmithKline Beecham Corp.
Infrared spectroscopy is a sensitive probe for the presence of bridging carbonyl ligands. For compounds with doubly bridging CO ligands, denoted μ2-CO or often just μ-CO, the bond stretching frequency νCO is usually shifted by 100–200 cm−1 to lower energy compared to the signatures of terminal CO, which are in the region 1800 cm−1. Bands for face-capping (μ3) CO ligands appear at even lower energies. In addition to symmetrical bridging modes, CO can be found to bridge asymmetrically or through donation from a metal d orbital to the π* orbital of CO. The increased π-bonding due to back-donation from multiple metal centers results in further weakening of the C–O bond.
== Pharmacokinetics == Loop diuretics are highly protein bound and therefore have a low volume of distribution. The protein bound nature of the loop diuretic molecules causes it to be secreted via several transporter molecules along the luminal wall of the proximal convoluted tubules to be able to exert its function. Loop diuretics usually have a ceiling effect whereby doses greater than a certain maximum amount will not increase the clinical effect of the drug. Also, there is a threshold minimum concentration of loop diuretics that needs to be achieved at the thick ascending limb to enable the onset of abrupt diuresis. The availability of furosemide is highly variable, ranging from 10% to 90%. The biological half-life of furosemide is limited by absorption from the gastrointestinal tract into the bloodstream. The apparent half-life of its excretion is higher than the apparent half-life of absorption via the oral route. Therefore, furosemide taken intravenously is twice as potent as an equivalent dose taken orally. However, for torsemide and bumetanide, their oral bioavailability is consistently higher than 90%. Torsemide has a longer half life in heart failure patients (6 hours) than furosemide (2.7 hours). A 40 mg dose of furosemide is clinically equivalent to a 20 mg dose of torsemide and to a 1 mg dose of bumetanide.
Sources: en.wikipedia.org
Anti-doping and clinical laboratories commonly use liquid chromatography-tandem mass spectrometry. The method can identify GW501516 and its metabolites in urine or blood. Detection depends on sample timing and the amount present.
PPARδ is a nuclear receptor that regulates genes linked to fatty acid oxidation and energy metabolism. Activation can alter lipid handling and energy use in experimental models. The full range of effects in humans is still under study.
The solid compound is generally stable when kept cold, dry, and protected from light. Solutions may degrade faster, so laboratory protocols often specify fresh preparation or cold storage. Stability can depend on solvent, concentration, and container.
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.